Sandesh Mahatme's most recent trade in CRISPR Therapeutics AG was a trade of 13,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 30, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
CRISPR Therapeutics AG | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
Aeglea BioTherapeutics Inc | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 43,000 | 43,000 | - | - | Director Stock Option (right to buy) | |
Aeglea BioTherapeutics Inc | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 40,000 | 40,000 | - | - | Director Stock Option (right to buy) | |
Aeglea BioTherapeutics Inc | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 28,100 | 28,100 | - | - | Director Stock Option (right to buy) |